您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > SDZ281-977(SDZ-LAP 977)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
SDZ281-977(SDZ-LAP 977)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
SDZ281-977(SDZ-LAP 977)图片
CAS NO:150779-71-8
规格:98%
分子量:316.35
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
20mg电议

产品介绍
SDZ281-977是EGF受体酪氨酸激酶抑制剂LavendustinA的衍生物。
CAS:150779-71-8
分子式:C18H20O5
分子量:316.35
纯度:98%
存储:Store at -20°C

Background:

SDZ 281-977 is a derivative of the EGF receptor tyrosine kinase inhibitor Lavendustin A.


The anticancer profile of SDZ 281-977 is investigated in nude mice bearing the human tumor cell lines A431 (vulvar carcinoma cells), MIA PaCa-2 (pancreatic tumor cells) and MDA-MB-231 (breast carcinoma cells). These cell lines are selected because of their sensitivity for SDZ 281-977. The IC50 values for inhibition of growth of A431, MIA PaCa-2 and MDA-MB-231 cells are 0.21 μM, 0.29 μM and 0.43 μM, respectively[1].


Nude mice bearing A431 human vulvar carcinomas receive intravenous injections of SDZ 281-977 (1-10 mg/kg) for 4 weeks. This treatment results in a dose-dependent inhibition of tumor growth. Orally administered SDZ 281-977 (30 mg/kg) induces a 54% inhibition of A431 tumor growth after 3 weeks of treatment. The above regimens are well tolerated. No significant change in body weight occurred during treatment[1].


[1]. Cammisuli S, et al. SDZ 281-977: a modified partial structure of lavendustin A that exerts potent and selective antiproliferative activities in vitro and in vivo. Int J Cancer. 1996 Jan 26;65(3):351-9.